uric acid has been researched along with atorvastatin in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.70) | 18.2507 |
| 2000's | 9 (24.32) | 29.6817 |
| 2010's | 20 (54.05) | 24.3611 |
| 2020's | 7 (18.92) | 2.80 |
| Authors | Studies |
|---|---|
| Bateman, ME; Byrnes, P; Firth, JC; Marais, AD; Martens, C; Mountney, J | 1 |
| Elisaf, M; Kakafika, A; Tsimihodimos, V | 1 |
| Elisaf, M; Kakafika, A; Liamis, G; Mikhailidis, D | 1 |
| Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K | 1 |
| Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Milionis, HJ; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Athyros, VG; Bairaktari, ET; Elisaf, MS; Kakafika, AI; Milionis, HJ; Seferiadis, KI; Tsouli, SG | 1 |
| Daskalopoulou, SS; Elisaf, M; Mikhailidis, DP; Tzovaras, V | 1 |
| Athyros, VG; Elisaf, M; Ganotakis, ES; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Papageorgiou, AA; Tziomalos, K | 1 |
| Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF | 1 |
| Todd, DJ | 1 |
| López-Cuenca, A; Marín, F; Roldán, V | 1 |
| Fujimori, S; Kaneko, K; Ogata, N; Oka, Y | 1 |
| Alexandrides, T; Athyros, VG; Bacharoudis, G; Ganotakis, ES; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Tziomalos, K | 1 |
| Elisaf, M; Katsiki, N | 1 |
| Takagi, H; Umemoto, T | 1 |
| Ike, A; Iwata, A; Kawamura, A; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Tanaka, T | 1 |
| Banach, M; Bielecka-Dabrowa, A; Mikhailidis, DP; Rizzo, M; Rysz, J; von Haehling, S | 1 |
| An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Cong, H; Fu, N; Jin, D; Li, H; Li, X; Ma, H; Wang, Y | 1 |
| Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN | 1 |
| Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W | 1 |
| Deedwania, PC; Fayyad, RS; Laskey, RE; Stone, PH; Wilson, DJ | 1 |
| Gilowski, W; Krysiak, R; Okopień, B | 1 |
| Gillen, M; Kerr, B; Shen, Z; Wallach, K; Yeh, LT; Zhu, N | 1 |
| Derosa, G; Maffioli, P; Reiner, Ž; Sahebkar, A; Simental-Mendía, LE | 1 |
| Athyros, VG; Giouleme, O; Grammatikos, N; Katsoula, A; Paschos, P; Tsimperidis, A | 1 |
| Ertas, K; Semercioz, A; Temiz, MZ; Yuruk, E; Zengi, O | 1 |
| Ashcroft, JA | 1 |
| Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B | 1 |
| Kasahara, M; Kuwabara, Y; Nakao, K; Ueshima, K; Yasuno, S | 1 |
| Krysiak, R; Okopień, B; Szkróbka, W | 1 |
| Kowalcze, K; Krysiak, R; Okopień, B | 3 |
| Adeyemi, DH; Afolabi, OA; Akhigbe, RE; Anyogu, DC; Hamed, MA; Odetayo, AF | 1 |
| Abdel-Gabbar, M; Abdelaziz, MA; Abdelzaher, MH; Ahmed, OM; Geddawy, AI; Ibrahim, SR; Moawd, SA; Mohammad, MR; Mohideen, AP | 1 |
4 review(s) available for uric acid and atorvastatin
| Article | Year |
|---|---|
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Losartan; Pyrroles; Uric Acid | 2005 |
Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2012 |
Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperuricemia; Randomized Controlled Trials as Topic; Simvastatin; Uric Acid | 2016 |
Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Topics: Allopurinol; Atorvastatin; Biomarkers; Gout Suppressants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Factors; Treatment Outcome; Uric Acid | 2018 |
12 trial(s) available for uric acid and atorvastatin
| Article | Year |
|---|---|
Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Uric Acid | 1997 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2003 |
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Topics: Atorvastatin; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2004 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Uric Acid; Ventricular Remodeling | 2008 |
Hypouricemic effect of statins: another pleiotropic benefit?
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperuricemia; Lipids; Pyrroles; Time Factors; Treatment Outcome; Uric Acid | 2010 |
Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2010 |
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Uric Acid | 2011 |
The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cardiomyopathy, Dilated; Cytokines; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Inflammation; Male; Middle Aged; Pyrroles; Uric Acid; Ventricular Function, Left | 2013 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid | 2015 |
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pravastatin; Renal Insufficiency, Chronic; Uric Acid | 2015 |
The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperlipidemias; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2020 |
21 other study(ies) available for uric acid and atorvastatin
| Article | Year |
|---|---|
Effect of atorvastatin on serum uric acid levels.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Uric Acid | 2001 |
Effect of atorvastatin on serum creatinine levels.
Topics: Anticholesteremic Agents; Atorvastatin; Creatinine; Heptanoic Acids; Humans; Pyrroles; Retrospective Studies; Uric Acid | 2001 |
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Topics: Aged; Atorvastatin; Coronary Disease; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Uric Acid | 2004 |
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluati
Topics: Aged; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Creatinine; Female; Glomerular Filtration Rate; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Uric Acid | 2007 |
Serum uric acid level reduction, cardiovascular outcome, and mortality: comment on the article by Ioachimescu et al.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Predictive Value of Tests; Pyrroles; Treatment Outcome; Uric Acid | 2008 |
Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease.
Topics: Atorvastatin; Cholesterol, LDL; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Pyrroles; Uric Acid | 2011 |
Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin.
Topics: Aged; Angina, Stable; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Down-Regulation; Female; Fibrosis; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Serum Amyloid P-Component; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Uric Acid | 2012 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperuricemia; Kidney; Male; Middle Aged; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2014 |
Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.
Topics: Acute Kidney Injury; Aged; Antioxidants; Atorvastatin; Biomarkers; Contrast Media; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Function Tests; Male; Middle Aged; Perioperative Period; Probucol; Prospective Studies; Pyrroles; Risk Factors; Uric Acid | 2014 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2014 |
The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism.
Topics: Aged; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Humans; Hypogonadism; Lipids; Male; Metabolic Diseases; Middle Aged; Risk Factors; Testosterone; Treatment Outcome; Uric Acid | 2016 |
In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters.
Topics: Adolescent; Adult; Aged; Atorvastatin; Carrier Proteins; Cell Line; Diuretics; Drug Interactions; Furosemide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kidney; Liver; Liver-Specific Organic Anion Transporter 1; Male; Metformin; Middle Aged; Thioglycolates; Triazoles; Uric Acid; Uricosuric Agents; Young Adult | 2016 |
Effects of statin treatment with atorvastatin on urolithiasis-associated urinary metabolic risk factors: an experimental study.
Topics: Animals; Atorvastatin; Calcium; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Rats; Rats, Sprague-Dawley; Risk Factors; Treatment Outcome; Uric Acid; Urinalysis; Urolithiasis | 2018 |
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Gout; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Purinergic P2Y Receptor Antagonists; Risk Factors; Uric Acid | 2018 |
The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study.
Topics: Adrenal Hyperplasia, Congenital; Adult; Androgens; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pilot Projects; Risk Factors; Testosterone; Uric Acid; Vitamin D | 2019 |
The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome.
Topics: Adult; Aged; Androgens; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiometabolic Risk Factors; Female; Fibrinogen; Homocysteine; Humans; Hydroxycholecalciferols; Insulin Resistance; Lipids; Male; Middle Aged; Polycystic Ovary Syndrome; Risk Factors; Testosterone; Uric Acid | 2021 |
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Insulin Resistance; Pilot Projects; Prolactin; Risk Factors; Uric Acid | 2022 |
Atorvastatin-mediated downregulation of VCAM-1 and XO/UA/caspase 3 signaling averts oxidative damage and apoptosis induced by ovarian ischaemia/reperfusion injury.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Apoptosis; Atorvastatin; Caspase 3; Down-Regulation; Female; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Ischemia; Malondialdehyde; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; Reperfusion Injury; Tumor Necrosis Factor-alpha; Uric Acid; Vascular Cell Adhesion Molecule-1; Xanthine Oxidase | 2022 |
Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis.
Topics: Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholesterol; Female; Fibrinogen; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors; Thyroiditis, Autoimmune; Uric Acid | 2023 |
The preventive effects of Ulva lactuca aqueous extract, ulvan polysaccharides and atorvastatin on ethylene glycol-induced hyperoxaluria.
Topics: Animals; Antioxidants; Atorvastatin; Body Weight; Creatinine; Ethylene Glycol; Humans; Hyperoxaluria; Kidney; Male; Oxalates; Polysaccharides; Rats; Rats, Wistar; Ulva; Urea; Uric Acid; Weight Loss | 2023 |
The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Female; Fibrinogen; Humans; Insulin Resistance; Polycystic Ovary Syndrome; Risk Factors; Siblings; Testosterone; Uric Acid | 2023 |